<DOC>
	<DOCNO>NCT02119104</DOCNO>
	<brief_summary>The purpose study investigate post marketing use safety Prevnar ( 13v ) infant vaccinate first time age 2 month , inclusive , 7 month , exclusive .</brief_summary>
	<brief_title>Prevenar ( 13v ) Infant Drug Use Investigation</brief_title>
	<detailed_description>The investigation conduct use continuous investigation method , satisfy registration condition continuously register number contract case reach .</detailed_description>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Vaccinees meet follow condition time first vaccination among infant use Prevenar 13 accordance indication , dosage administration vaccine include investigation : Infants age 2 month , inclusive , 7 month , exclusive Infants history administration pneumococcal vaccine include Prevenar 13 Infants expect receive 4 vaccination Vaccines must perform vaccinee corresponds follow : Persons past history anaphylaxis due ingredient Prevenar 13 diphtheria toxoid evident Persons evident pyrexia Persons evidently serious acute disease Besides person list , person status inappropriate immunization</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>